Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Incannex Healthcare (IXHL) Cash & Equivalents (2020 - 2025)

Incannex Healthcare's Cash & Equivalents history spans 4 years, with the latest figure at $68.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 3184.08% to $68.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $68.9 million, a 3184.08% increase, with the full-year FY2025 number at $15.0 million, up 156.73% from a year prior.
  • Cash & Equivalents hit $68.9 million in Q4 2025 for Incannex Healthcare, down from $73.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IXHL hit a ceiling of $73.3 million in Q3 2025 and a floor of $2.1 million in Q4 2024.
  • Historically, Cash & Equivalents has averaged $22.1 million across 3 years, with a median of $11.9 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: plummeted 85.58% in 2024 and later surged 3184.08% in 2025.
  • Tracing IXHL's Cash & Equivalents over 3 years: stood at $14.6 million in 2023, then plummeted by 85.58% to $2.1 million in 2024, then surged by 3184.08% to $68.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for IXHL at $68.9 million in Q4 2025, $73.3 million in Q3 2025, and $15.0 million in Q2 2025.